The U.S. Food and Drug Administration has approved Eli Lilly’s once-weekly basal insulin, Onswik, for adults with type 2 diabetes.
The decision gives patients a long-acting option that can replace daily basal injections with one dose a week. The medicine, whose chemical name is insulin efsitora alfa-gobe, is intended to be used with diet and exercise to control blood sugar.
The approval rests on a late-stage programme involving more than 3,400 adults across four studies. Lilly said the treatment met each study’s main endpoint by producing reductions in A1C that were not inferior to daily insulin glargine, a widely used long-acting insulin.
The label is not unlimited. Onswik is not approved for type 1 diabetes, and Lilly says it should not be used in that population because of an increased risk of severe hypoglycaemia. As with other insulin products, dosing and monitoring will remain clinical decisions rather than a simple swap based on convenience.
Lilly plans to make the product available in the United States in the coming months in a pre-filled pen and in two concentrations. The same medicine has already received regulatory clearance in Europe, Japan and Mexico.
The significance of the FDA action is practical as much as scientific. Reducing more than 300 injections a year may help some patients remain on treatment, but the effect will also depend on pricing, insurance coverage and the warnings that accompany use. Approval permits marketing under the authorised conditions; it does not establish that the weekly product is the right choice for every adult with type 2 diabetes.
